Ensysce Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
ENSC$0.36-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional · Accumulated · Noncontrolling | ||||||
| Number of Shares | Amount | Paid-In Capital | Deficit | interests | Total | |
| Balance on June 30, 2024 | 543,412 | $54 | $128,449,460 | $(126,641,646) | $(328,483) | $1,479,385 |
| Public offering | 236,881 | 24 | 1,669,977 | - | - | 1,670,001 |
| Issuance of common stock upon inducement of warrants | 144,412 | 14 | 3,385,633 | - | - | 3,385,647 |
| Transaction costs associated with public offering and warrant inducement | - | - | (637,894) | - | - | (637,894) |
| Stock-based compensation | - | - | 20,819 | - | - | 20,819 |
| Reversed stock-split rounding adjustment | (4) | - | - | - | - | - |
| Net income | - | - | - | 661,769 | - | 661,769 |
| Balance on September 30, 2024 | 924,701 | $92 | $132,887,995 | $(125,979,877) | $(328,483) | $6,579,727 |
| Balance on June 30, 2025 | 2,393,256 | $241 | $136,612,043 | $(133,223,223) | $(328,649) | $3,060,412 |
| Issuance of common stock upon exercise of warrants | 787,818 | 79 | 1,496,775 | - | - | 1,496,854 |
| Consultant settlement | - | - | 718 | - | - | 718 |
| Stock-based compensation | - | - | 45,858 | - | - | 45,858 |
| Net loss | - | - | - | (3,729,128) | - | (3,729,128) |
| Balance on September 30, 2025 | 3,181,074 | $320 | $138,155,394 | $(136,952,351) | $(328,649) | $874,714 |
| Balance on December 31, 2023 | 209,739 | 21 | $121,234,195 | $(121,557,074) | (328,409) | (651,267) |
| Settlement of restricted stock units | 5 | - | - | - | - | - |
| Conversion of convertible notes | 49,702 | 5 | 1,168,595 | - | - | 1,168,600 |
| Public offering | 236,881 | 24 | 1,669,977 | 1,670,001 | ||
| Issuance of common stock upon exercise of warrants | 88,262 | 9 | 2,075,210 | - | - | 2,075,219 |
| Issuance of common stock upon warrant inducement, net of issuance cost | 340,121 | 33 | 8,103,910 | - | 8,103,943 | |
| Transaction costs associated with warrant inducement | - | - | (1,444,756) | - | - | (1,444,756) |
| Stock-based compensation | - | - | 80,574 | - | - | 80,574 |
| Reversed stock-split rounding adjustment | (9) | - | - | - | - | - |
| Deemed dividend related to warrant down round provision | - | - | 290 | (290) | - | - |
| Net loss | - | - | - | (4,422,513) | (74) | (4,422,587) |
| Balance on September 30, 2024 | 924,701 | $92 | $132,887,995 | $(125,979,877) | $(328,483) | $6,579,727 |
| Balance on December 31, 2024 | 1,355,773 | 136 | $133,252,585 | $(129,544,299) | (328,483) | 3,379,939 |
| Public offering | 239,594 | 25 | 1,099,982 | - | - | 1,100,007 |
| Issuance of common stock upon exercise of warrants | 935,331 | 94 | 1,887,615 | - | - | 1,887,709 |
| Transaction costs associated with public offering | - | - | (204,193) | - | - | (204,193) |
| Issuance of common stock upon warrant inducement, net of issuance cost | 630,376 | 63 | 2,199,949 | - | - | 2,200,012 |
| Transaction costs associated with warrant inducement | - | - | (297,021) | - | - | (297,021) |
| Consultant compensation | 20,000 | 2 | 63,730 | - | - | 63,732 |
| Stock-based compensation | - | - | 152,747 | - | - | 152,747 |
| Net loss | - | - | - | (7,408,052) | (166) | (7,408,218) |
| Balance on September 30, 2025 | 3,181,074 | $320 | $138,155,394 | $(136,952,351) | $(328,649) | $874,714 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.